248 related articles for article (PubMed ID: 34806498)
1. Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer.
Matusz-Fisher A; Tan AR
Expert Opin Biol Ther; 2022 Mar; 22(3):385-395. PubMed ID: 34806498
[TBL] [Abstract][Full Text] [Related]
2. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading.
Force J; Leal JHS; McArthur HL
Curr Treat Options Oncol; 2019 Mar; 20(4):35. PubMed ID: 30923913
[TBL] [Abstract][Full Text] [Related]
4. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of immune checkpoint inhibitors for the treatment of breast cancer.
Howard FM; Villamar D; He G; Pearson AT; Nanda R
Expert Opin Investig Drugs; 2022 Jun; 31(6):531-548. PubMed ID: 34569400
[TBL] [Abstract][Full Text] [Related]
6. Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors.
Zhao S; Qiu Y; Yuan M; Wang Z
Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
Varma R; Wright M; Abraham J; Kruse M
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy as a partner for HER2-directed therapies.
Clifton GT; Peoples AGE
Expert Rev Anticancer Ther; 2021 Jul; 21(7):739-746. PubMed ID: 33666116
[No Abstract] [Full Text] [Related]
9. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
[TBL] [Abstract][Full Text] [Related]
10. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.
Krasniqi E; Barchiesi G; Pizzuti L; Mazzotta M; Venuti A; Maugeri-Saccà M; Sanguineti G; Massimiani G; Sergi D; Carpano S; Marchetti P; Tomao S; Gamucci T; De Maria R; Tomao F; Natoli C; Tinari N; Ciliberto G; Barba M; Vici P
J Hematol Oncol; 2019 Oct; 12(1):111. PubMed ID: 31665051
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in Gastric Cancer.
Högner A; Moehler M
Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
[TBL] [Abstract][Full Text] [Related]
13. Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.
Noguchi E; Shien T; Iwata H
Jpn J Clin Oncol; 2021 Mar; 51(3):321-332. PubMed ID: 33324990
[TBL] [Abstract][Full Text] [Related]
14. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
15. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
16. Emerging Therapeutic Options for HER2-Positive Breast Cancer.
Martin M; López-Tarruella S
Am Soc Clin Oncol Educ Book; 2016; 35():e64-70. PubMed ID: 27249772
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
[TBL] [Abstract][Full Text] [Related]
19. [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
Zhang D; Huang J; Zhang C; Guan Y; Guo Q
Zhongguo Fei Ai Za Zhi; 2019 Jun; 22(6):369-379. PubMed ID: 31196371
[TBL] [Abstract][Full Text] [Related]
20. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
Hamilton EP; Kaklamani V; Falkson C; Vidal GA; Ward PJ; Patre M; Chui SY; Rotmensch J; Gupta K; Molinero L; Li Y; Emens LA
Clin Breast Cancer; 2021 Dec; 21(6):539-551. PubMed ID: 34154926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]